Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
XFOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $1.60
Previous CloseN/A
Volume769.31K
Average Volume (3M)1.53M
Market Cap
$47.08M
Enterprise Value$124.90M
Total Cash (Recent Filing)$99.47M
Total Debt (Recent Filing)$58.28M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
May 08, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding173,662,370
10 Day Avg. Volume1,764,792
30 Day Avg. Volume1,532,262
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)46.67
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-62.57
Enterprise Value/Ebitda-0.93
Forecast
1Y Price Target
$2.70Price Target Upside900.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
X4 Pharmaceuticals News
PremiumCompany Announcements
X4 Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
X4 Pharmaceuticals Reports 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported total revenue of $1.4M, compared to the consensus estimate of $1.06M, and a net income of $0.20 per share, compared to the consensus estimated a net loss of $0.18 per share.
Revenue GrowthXOLREMDI sales increased significantly, surpassing estimates, due to commercialization progress and inventory build.
Strategic PartnershipsX4 Pharmaceuticals has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of mavorixafor in Europe, Australia, and New Zealand.
Bears Say
Capital RequirementsDespite the collaboration, additional capital is still considered necessary to provide sufficient runway to topline data from the P3 4WARD trial.
Market AdoptionMarket adoption of the drug has not been as robust as expected.
Operational ChallengesThe longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.
---
Ownership Overview
14.82% Insiders
7.41% Mutual Funds
31.82% Other Institutional Investors
37.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $0.24 and its highest was $1.60 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $47.08M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Mar 25, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.024.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.12.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 173,662,370 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -13.333%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
---
X4 Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.70 (900.00% Upside)
$2.70 (900.00% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.78%
12-Months-Change
Fundamentals
Return on Equity
-102.26%
Trailing 12-Months
Asset Growth
-0.55%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
---
XFOR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
X4 Pharmaceuticals showed strong progress with the launch of XOLREMDI and international expansion efforts. Positive clinical trial results and strategic restructuring indicate potential for future growth. However, the company faces challenges with net losses, market penetration, and adjustments in clinical trial protocols.Read More>---
XFOR Stock 12 Month Forecast
Average Price Target
$2.70
▲(900.00% Upside)
Technical Analysis
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Agios Pharma
―
Karyopharm Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering XFOR
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-23.83%
reiterated a buy rating 4 days ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -23.83% per trade.
---